

Financial Tear Sheet

Corporate Profile

We develop novel products based on our proprietary technologies for precision metering of gas flow. Our first commercial product, the **CoSense®** ETCO Monitor, measures end-tidal carbon dioxide (ETCO) in exhaled breath. The **CoSense** Monitor aids in the detection hemolysis, which is the breakdown of red blood cells. When present in babies with jaundice, hemolysis is a dangerous condition that can lead to long-term developmental disabilities. The **CoSense** Monitor also aids in the detection of smoke inhalation and carbon monoxide poisoning. We have recently commenced commercial sales of the **CoSense** devices and sampling sets. The **CoSense** Monitor is the first 510(k) cleared and CE mark approved device based on our Sensalyze™ Technology Platform. Our Sensalyze Technology Platform combines hardware, sensors, and software to provide a novel platform for non-invasive breath-based detection of various analytes. Our current development pipeline includes proposed devices for asthma in children, assessment of blood carbon dioxide, or CO₂, concentration in neonates, and malabsorption in infants.

Primary IR Contact

Investors

E-mail: ir@capnia.com

Our therapeutic technology is based upon the observation that non-inhaled CO₂ delivered at a low-flow rate into the nasal cavity alleviates the symptoms related to allergies as well as trigeminally mediated pain conditions such as trigeminal neuralgia, cluster headache and migraine. We are currently developing the technology for these indications.

Stock Performance

SLNO (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$0.55
Change (%)	▼ 0.02 (3.51%)
Volume	14,188
52 Week Low	\$0.54
Market Cap	\$27,339,103
Rolling EPS	-0.90
PE Ratio	0
Shares Outstanding	47,587,647

Data as of 06/22/17 3:59 p.m. ET



Recent Headlines

05/11/17 - 4:05 p.m.

Capnia Provides Corporate Update and Reports First Quarter 2017 Financial Results

03/15/17 - 4:11 p.m.

Capnia Reports Fourth Quarter and Full Year 2016 Financial Results

03/08/17 - 7:00 a.m.

Capnia Completes Merger with Essentialis Creating Rare Disease Therapeutics Company

Recent Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
06/13/17	S-1/A
05/15/17	424B3
05/15/17	424B3
05/15/17	424B3

Corporate Governance

Anish Bhatnagar, MD	Chief Executive Officer
David O'Toole	Chief Financial Officer
Kristen Yen	Vice President, Clinical and Regulatory Affairs
Otho Boone	General Manager, Neonatology
Anthony "Tony" Wondka	Vice President, Research and Development

Data provided by Nasdaq. Minimum 15 minutes delayed.